Key result
Long-term cardiac contractility modulation significantly improved left ventricular ejection fraction by an estimated mean of 4.9% at 24 months in patients with heart failure.
Why the study?
Does cardiac contractility modulation (CCM) improve symptoms, quality of life, and left ventricular ejection fraction in patients with heart failure and reduced ejection fraction?
Observational (n=143)
Yes
Does cardiac contractility modulation (CCM) improve symptoms, quality of life, and left ventricular ejection fraction in patients with heart failure and reduced ejection fraction?
Answers are grounded in this paper and cite their sources.
Long-term cardiac contractility modulation provides sustained symptomatic and functional improvement in heart failure patients over 2 years, independent of baseline LVEF being above or below 35%.
Heart failure is a major cause of morbidity and mortality throughout the world. Despite advances in therapy, nearly half of patients receiving guideline-directed medical therapy remain limited by symptoms. Cardiac contractility modulation (CCM) can improve symptoms in this population, but efficacy and safety in prospective studies has been limited to 12 months of follow-up. We report on the first 2 year multi-site evaluation of CCM in patients with heart failure. One hundred and forty-three subjects with heart failure and reduced ejection fraction were followed via clinical registry for 24 months recording NYHA class, MLWHFQ score, 6 min walk distance, LVEF, and peak VO 2 at baseline and 6 month intervals as clinically indicated. Serious adverse events, and all cause as well as cardiovascular mortality were recorded. Data are presented stratified by LVEF (all subjects, LVEF <35%, LVEF ≥35%). One hundred and six subjects from 24 sites completed the 24 month follow-up. Baseline parameters were similar among LVEF groups. NYHA and MLWHFQ improved in all 3 groups at each time point. LVEF in the entire cohort improved 2.5, 2.9, 5.0, and 4.9% at 6, 12, 18, and 24 months, respectively. Insufficient numbers of subjects had follow-up data for 6 min walk or peak VO 2 assessment, precluding comparative analysis. Serious adverse events ( n = 193) were observed in 91 subjects and similarly distributed between groups with LVEF <35% and LVEF ≥35%, and similar to other device trials for heart failure. Eighteen deaths (7 cardiovascularly related) over 2 years. Overall survival at 2 years was 86.4% (95% confidence intervals: 79.3, 91.2%). Cardiac contractility modulation provides safe and effective long-term symptomatic and functional improvement in heart failure. These benefits were independent of baseline LVEF and were associated with a safety profile similar to published device trials.
No takes yet. Share an insight, caveat, or question.
Remppis et al. (2017) conducted an observational in Heart failure with reduced ejection fraction (n=143). Cardiac contractility modulation (CCM) vs. Baseline (no control group) was evaluated on Change in left ventricular ejection fraction at 24 months (4.9% mean improvement, p=<0.001). Long-term cardiac contractility modulation significantly improved left ventricular ejection fraction by an estimated mean of 4.9% at 24 months in patients with heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: